Keymed Biosciences, Inc. (HK:2162) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Keymed Biosciences Inc. has entered an exclusive license agreement with Platina Medicines Ltd, granting them rights to develop, manufacture, and commercialize the bispecific antibody CM336 outside China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of $16 million to Keymed and potential milestone payments up to $610 million, along with royalties on sales. This agreement aims to expand Keymed’s global presence and maximize the commercial potential of its technology.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.